Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. (April 2021)

• Record Type: Journal Article
• Authors: Court, Richard; Centner, Chad M.; Chirehwa, Maxwell; Wiesner, Lubbe; Denti, Paolo; de Vries, Nihal; Harding, Joseph; Gumbo, Tawanda; Maartens, Gary; McIlleron, Helen
• Is Part Of: International journal of infectious diseases. Volume 105(2021)
• Page Start: 688
• Page End: 694
• Publication Date: 2021-04
• Subjects: Cycloserine -- Terizidone -- Pyridoxine -- Pharmacokinetics -- Neuropathy -- Neuropsychiatric; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.03.001
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Neuropsychiatric events are common in patients with multidrug-resistant tuberculosis treated with cycloserine. Cycloserine clearance is significantly associated with peripheral neuropathy. High-dose pyridoxine is toxic to peripheral nerves. Cycloserine accumulation could be an important mechanism of toxicity. Interventions to increase cycloserine clearance could assist toxicity management. Abstract: Background: Cycloserine, or its structural analogue terizidone, has been associated with neuropsychiatric toxicity (psychosis, depression, and neuropathy). Prospective clinical data on the incidence of and risk factors for neuropsychiatric toxicity in TB patients treated with cycloserine are limited. Methods: A prospective evaluation of neuropsychiatric toxicity was performed using validated screening tools in patients with multidrug-resistant tuberculosis treated with terizidone. Cox proportional hazard modelling was performed to explore the effects of clinical variables and measures of cycloserine pharmacokinetics in plasma. Results: A total 144 participants were recruited: 86 were male and 58 were female; their median age was 35.7 years and 91 (63%) were HIV-infected. Fifty-five (38%) participants developed at least one neuropsychiatric event (30 cases per 100 person-months): 50 (35%) neuropathy, 14 (10%) depression, and 11 (8%) psychosis. Neuropathy was independently associated with cycloserine clearance ((adjusted hazard ratio 0.34 (aHR), P = 0.03)) and high-dose pyridoxine (200 mg vs 150 mg daily, aHR: 2.79, P = 0.01). Conclusions: A high incidence of early neuropsychiatric toxicity was observed in this cohort of patients treated with terizidone. Cycloserine clearance and higher doses of pyridoxine are associated with incident or worsening peripheral neuropathy.